MA38215A1 - Composition pharmaceutique ophtalmologique topique contenant regorafenib - Google Patents

Composition pharmaceutique ophtalmologique topique contenant regorafenib

Info

Publication number
MA38215A1
MA38215A1 MA38215A MA38215A MA38215A1 MA 38215 A1 MA38215 A1 MA 38215A1 MA 38215 A MA38215 A MA 38215A MA 38215 A MA38215 A MA 38215A MA 38215 A1 MA38215 A1 MA 38215A1
Authority
MA
Morocco
Prior art keywords
topical ophthalmic
ophthalmic pharmaceutical
pharmaceutical composition
composition containing
containing regorafenib
Prior art date
Application number
MA38215A
Other languages
English (en)
Inventor
Jörg Keldenich
Bernd Riedl
Michael Böttger
Julia Freundlieb
Uwe Muenster
Annett Richter
Claudia Hirth-Dietrich
Andreas Ohm
Degenfeld Georges Von
Jürgen Klar
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MA38215A1 publication Critical patent/MA38215A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques ophtalmologiques topiques contenant régorafénib, un hydrate, solvate ou sel pharmaceutiquement acceptable de celui-ci, ou un polymorphe de celui-ci mais sans silice hydrophobe et son procédé de préparation et son utilisation pour le traitement de troubles ophtalmologiques
MA38215A 2012-12-21 2015-06-19 Composition pharmaceutique ophtalmologique topique contenant regorafenib MA38215A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12198892 2012-12-21
PCT/US2013/077358 WO2014100797A1 (fr) 2012-12-21 2013-12-21 Composition pharmaceutique ophtalmologique topique contenant régorafénib

Publications (1)

Publication Number Publication Date
MA38215A1 true MA38215A1 (fr) 2017-01-31

Family

ID=47458742

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38215A MA38215A1 (fr) 2012-12-21 2015-06-19 Composition pharmaceutique ophtalmologique topique contenant regorafenib

Country Status (27)

Country Link
US (2) US20140179745A1 (fr)
EP (1) EP2934481A1 (fr)
JP (1) JP2016507505A (fr)
KR (1) KR20150100670A (fr)
CN (1) CN104955443A (fr)
AP (1) AP2015008493A0 (fr)
AR (1) AR094104A1 (fr)
AU (1) AU2013364004A1 (fr)
BR (1) BR112015014078A2 (fr)
CA (1) CA2895804A1 (fr)
CL (1) CL2015001701A1 (fr)
CR (1) CR20150327A (fr)
CU (1) CU20150063A7 (fr)
DO (1) DOP2015000155A (fr)
EA (1) EA201500669A1 (fr)
EC (1) ECSP15026386A (fr)
IL (1) IL238791A0 (fr)
MA (1) MA38215A1 (fr)
MX (1) MX2015007488A (fr)
PE (1) PE20151784A1 (fr)
PH (1) PH12015501407A1 (fr)
SG (1) SG11201503838WA (fr)
TN (1) TN2015000280A1 (fr)
TW (1) TW201431568A (fr)
UY (1) UY35183A (fr)
WO (1) WO2014100797A1 (fr)
ZA (1) ZA201505196B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458031A4 (fr) * 2016-05-16 2020-01-22 Delivra Inc. Formulations transdermiques pour l'administration de célécoxib et leur utilisation dans le traitement de maladies et de pathologies sensibles au celcoxib
CN112834485B (zh) * 2021-02-07 2022-03-29 西南交通大学 激光诱导击穿光谱元素定量分析的一种非定标方法
KR102413226B1 (ko) 2021-08-26 2022-06-23 충북대학교 산학협력단 레고라페닙을 유효성분으로 포함하는 항노화 조성물
KR20230166353A (ko) 2022-05-30 2023-12-07 (주) 레비레스코 감태 추출물, 귤피 추출물, 및 녹차 추출물을 유효성분으로 포함하는 자외선에 대한 세포 보호용 또는 mmp-1 발현 억제용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580384A (en) * 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
PL1885336T3 (pl) 2005-05-10 2009-08-31 Alcon Inc Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu
EP1893216A4 (fr) 2005-06-08 2012-08-08 Targegen Inc Methodes et preparations pour le traitement de troubles oculaires
US20080293691A1 (en) 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
EP1962828A1 (fr) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryle-uree pour le traitement de maladies inflammatoires de la peau, l'oeil et/ou l'oreille
WO2007076358A1 (fr) 2005-12-23 2007-07-05 Alcon, Inc. Preparation pharmaceutique pour l'administration, dans l'oeil, de composes inhibiteurs des récepteurs tyrosine kinases (rtki)
WO2008027341A2 (fr) 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP3165606A1 (fr) 2009-05-01 2017-05-10 Ophthotech Corporation Procédés de traitement ou de prévention de maladies ophtalmologiques
CN102573477A (zh) 2009-07-16 2012-07-11 葛兰素惠尔康制造业私人有限公司 治疗方法
JP5998213B2 (ja) * 2011-06-28 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ レゴラフェニブを含有する眼科用局所医薬組成物

Also Published As

Publication number Publication date
JP2016507505A (ja) 2016-03-10
US20150328145A1 (en) 2015-11-19
DOP2015000155A (es) 2015-08-31
EA201500669A1 (ru) 2015-12-30
CL2015001701A1 (es) 2015-10-16
MX2015007488A (es) 2015-09-04
AP2015008493A0 (en) 2015-05-31
IL238791A0 (en) 2015-06-30
AU2013364004A1 (en) 2015-06-04
AR094104A1 (es) 2015-07-08
WO2014100797A1 (fr) 2014-06-26
CR20150327A (es) 2015-09-14
TW201431568A (zh) 2014-08-16
PH12015501407A1 (en) 2015-09-07
ZA201505196B (en) 2017-11-29
CA2895804A1 (fr) 2014-06-26
UY35183A (es) 2014-07-31
SG11201503838WA (en) 2015-07-30
TN2015000280A1 (en) 2016-10-03
ECSP15026386A (es) 2016-01-29
BR112015014078A2 (pt) 2018-05-15
CU20150063A7 (es) 2015-11-27
KR20150100670A (ko) 2015-09-02
PE20151784A1 (es) 2015-11-25
EP2934481A1 (fr) 2015-10-28
CN104955443A (zh) 2015-09-30
US20140179745A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MA37888B1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
MA35576B1 (fr) Nouveaux composés
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA38215A1 (fr) Composition pharmaceutique ophtalmologique topique contenant regorafenib
WO2013188273A8 (fr) Composition pharmaceutique ophtalmique topique contenant de l'axitinib
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA37666B1 (fr) Sel de camsylate
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
WO2013188283A8 (fr) Composition pharmaceutique ophtalmique topique contenant du sunitinib
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MA37721B1 (fr) Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA38688A1 (fr) Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
WO2013188279A8 (fr) Composition pharmaceutique ophtalmique topique contenant du cediranib
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA38974A1 (fr) Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate
MA45867B1 (fr) Modulateurs du récepteur des oestrogènes
MA35894B1 (fr) Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c